SCHEMBL143730

SCHEMBL143730

COc1cccc(OC)c1CS(=O)(=O)c1ccc2c(c1)/C(=C/c1[nH]c(C)c(C(=O)N3CCC[C@@H]3CN3CCCC3)c1C)C(=O)N2

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 11/20 0.83
PDGFRB P09619 10/20 0.83
FGFR1 P11362 9/20 0.83
MET P08581 8/20 0.83
LCK P06239 3/20 0.83
YES1 P07947 3/20 0.83
SRC P12931 3/20 0.83
ALK Q9UM73 3/20 0.83
FLT3 P36888 3/20 0.83
KIT P10721 2/20 0.83
CDK2 P24941 2/20 0.83
PTK2B Q14289 2/20 0.83
MEN1 O00255 2/20 0.83
KMT2A Q03164 2/20 0.83
TDP1 Q9NUW8 2/20 0.83
EGFR P00533 2/20 0.83
AURKB Q96GD4 2/20 0.83
ABL1 P00519 2/20 0.83
RET P07949 2/20 0.83
PLK4 O00444 1/20 0.83

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL144256 0.92 KDR (0.88) KDRPDGFRBFGFR1METLCK
Pha-665752 SCHEMBL93656 0.91 KDR (1.00) KDRPDGFRBFGFR1METLCK
Pha-665752 SCHEMBL93654 0.91 KDR (1.00) KDRPDGFRBFGFR1METLCK
Pha-665752 SCHEMBL140412 0.91 KDR (1.00) KDRPDGFRBFGFR1METLCK
Pha-665752 SCHEMBL93657 0.91 KDR (1.00) KDRPDGFRBFGFR1METLCK
Pha-665752 SCHEMBL29376386 0.91 KDR (1.00) KDRPDGFRBFGFR1METLCK
SCHEMBL142206 0.91 KDR (0.85) KDRPDGFRBFGFR1METLCK
Pha-665752 SCHEMBL93655 0.91 KDR (1.00) KDRPDGFRBFGFR1METLCK
Pha-665752 SCHEMBL15639801 0.90 KDR (0.99) KDRPDGFRBFGFR1METLCK
Pha-665752 SCHEMBL15639803 0.90 KDR (0.99) KDRPDGFRBFGFR1METLCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6599902-B2 For treating or preventing a protein kinase related disorder SUGEN, INC. 2003-07-29 US claimed
US-20030125370-A1 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS SUGEN, INC. 2003-07-03 US claimed
US-20140221455-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR Verva Pharmaceuticals, Inc. (AU) 2014-08-07 US disclosed
US-20120059047-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR VERVA PHARMACEUTICALS PTY LTD (AU) 2012-03-08 US disclosed
US-20050282733-A1 Differentiation modulating agents and uses therefor VERVA PHARMACEUTICALS PTY LTD (AU) 2005-12-22 US disclosed
WO-2005065686-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR ADIPOGEN PHARMACEUTICALS PTY LIMITED (AU) 2005-07-21 WO disclosed
US-6599902-B2 For treating or preventing a protein kinase related disorder SUGEN, INC. 2003-07-29 US disclosed
WO-2002096361-A2 5-ARALKYLSULFONYL-3- (PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS SUGEN, INC. (US) 2002-12-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120059047-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR FGF1, FABP4, FGF2 KDR 1077/4885PDGFRB 467/4885FGFR1 5/4885
US-20050282733-A1 Differentiation modulating agents and uses therefor FGF1, FABP4, FGF2 KDR 1077/4885PDGFRB 467/4885FGFR1 5/4885
US-20030125370-A1 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS DMPK, ADK, MAP3K20 KDR 398/4885PDGFRB 348/4885FGFR1 637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.